ILLUMINATE Trial

Revision as of 11:56, 18 September 2013 by Rim Halaby (talk | contribs)
Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

ILLUMINATE Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of ILLUMINATE Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on ILLUMINATE Trial

CDC on ILLUMINATE Trial

ILLUMINATE Trial in the news

Blogs on ILLUMINATE Trial

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for ILLUMINATE Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Objective

Raising HDL levels by a combination of torcetrapib, a CETP inhibitor, and atorvastatin, an HGM-CoA reductase inhibitor.

Dates

Start Date

August 23, 2004

End Date

Premature Termination on December 2, 2006. Data collection continued till July 15, 2007.

Methods

Results

Study Outcomes

Conclusion

References